- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02799810
Psychosocial Evaluation Prior to Lung Transplantation (EVALUT)
Standardized Evaluation of Psychosocial Functioning in Patients Awaiting Lung Transplantation
Study Overview
Status
Conditions
Detailed Description
There is ample evidence that there are high rates of anxiety and depression among patients with end-stage lung disease. In addition, psychological dysfunction and distress seem to be especially prevalent in patients awaiting lung transplantation. Even though patients benefit from the transplant procedure with respect to long-term health-related quality of life (HRQoL), they also face significant challenges in terms of psychosocial adjustment after the transplantation. There is evidence that e.g. persistently elevated depressive symptoms are associated with reduced survival after lung transplantation.
Currently, the screening process to help select among candidates for organ transplant typically involves considering a variety of psychosocial factors. However, it remains somewhat unclear which criteria are considered important in these evaluations, how differences in various aspects of psychosocial functioning are weighed in making the ultimate decision on the suitability of a patient for transplantation, and the extent to which pretransplant psychosocial characteristics predict the medical and psychosocial outcomes of the procedure. Standardized psychometric instruments with proven reliability and validity can prevent the danger of personal bias in the selection of candidates for transplantation. In addition, structured psychometric instruments can help to identify patients with multiple care needs and can support the development of psychosocial interventions designed to increase quality of life and to decrease the risk of a less favorable transplant outcome through modifying the factors that might place patients at risk.
In a longitudinal prospective cohort study, psychosocial functioning will be assessed at multiple time points both before and after lung transplantation. Assessment of psychosocial functioning will be conducted using a validated, structured interview which allows a comprehensive evaluation of the level of adjustment in 10 aspects of psychosocial functioning - the Transplant Evaluation Rating Scale (TERS) - and standardized self-report instruments. The TERS has shown to be an important and significant predictor of several facets of somatic and psychosocial outcomes e.g. in patients after liver transplantation, left ventricular assist device implantation, and hematopoietic stem cell transplantation.
For each patient, a face-to-face psychosomatic evaluation 1 year after Transplantation will take place during a routine clinical assessments at the Department of Respiratory Medicine.
The following outcome parameters will be assessed:
- Mental disorders (current)
- Psychological processing of lung transplantation (including organ integration and the patient's relationship with the donor, chronic stress/psychological distress and the emotional effects of transplantation/immunosuppression
- Return to work one year after lung transplantation
- Psychological interventions during the first postoperative year
- Intake of (new) psychotropic medication during the first postoperative year
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients listed for lung Transplantation (including combined Transplantation) or who are evaluated at the interdisciplinary lung transplant outpatient clinic
- regular post-transplant visits at the Department of Respiratory Medicine
- informed consent
Exclusion Criteria:
- Age below 18 years
- lacking German language skills
- severe cognitive disability
- re-do Transplantation
- colonization with pan- or multi-resistant organisms with Need for isolation
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in survival status after lung transplantation
Time Frame: assessments at 1, 3, 6 and 12 month after lung transplantation
|
number of days survived during first post-operative year
|
assessments at 1, 3, 6 and 12 month after lung transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
duration of hospitalization after lung transplantation
Time Frame: assessments at 1, 3, 6 and 12 month after lung transplantation
|
number of days of hospitalization during first post-operative year
|
assessments at 1, 3, 6 and 12 month after lung transplantation
|
change in adherence during the first post-operative year
Time Frame: assessments at 1, 3, 6 and 12 month after lung transplantation
|
mean composite adherence score to immunosuppressants (IS) based on multiple clinical ratings and IS trough levels during first post-operative year
|
assessments at 1, 3, 6 and 12 month after lung transplantation
|
change from baseline quality of life to one year post-transplantation
Time Frame: once before admission to waiting list and 12 month after lung transplantation
|
Change in self-rated multidimensional quality of life
|
once before admission to waiting list and 12 month after lung transplantation
|
change in quality of life during first post-operative year
Time Frame: 1, 3, 6 and 12 month after lung transplantation
|
mean self-rated multidimensional quality of life based on multiple assessments during first post-operative year
|
1, 3, 6 and 12 month after lung transplantation
|
change from baseline psychological distress (questionnaire) to one year post-transplantation
Time Frame: once before admission to waiting list and 12 month after lung transplantation
|
change in levels of self-rated anxiety and depressive symptoms
|
once before admission to waiting list and 12 month after lung transplantation
|
change in psychological distress (questionnaire) during first post-operative year
Time Frame: 1, 3, 6 and 12 month after lung transplantation
|
mean levels of self-rated anxiety and depressive symptoms based on multiple assessments during first post-operative year
|
1, 3, 6 and 12 month after lung transplantation
|
mental disorders
Time Frame: 12 month after lung transplantation
|
number and kind of current mental disorders at one year after lung transplantation
|
12 month after lung transplantation
|
integration of transplant in own Body Image (questionnaire)
Time Frame: 12 month after lung transplantation
|
Quality of psychological processing of lung Transplantation and Feelings towards donor one year after lung transplantation
|
12 month after lung transplantation
|
psychological interventions
Time Frame: 12 month after lung transplantation
|
number and kind of psychosocial interventions during first post-operative year
|
12 month after lung transplantation
|
psychotropic medication
Time Frame: 12 month after lung transplantation
|
kind and intake of (new) psychotropic medication during first post-operative year
|
12 month after lung transplantation
|
change from baseline comorbidity to one year post-Transplantation (clinical Rating)
Time Frame: once before admission to waiting list and 12 month after lung transplantation
|
change in kind, number and degree of comorbid conditions
|
once before admission to waiting list and 12 month after lung transplantation
|
Change in comorbidity (clinical Rating)
Time Frame: 1, 3, 6 and 12 month after lung transplantation
|
mean number and degree of comorbid conditions during first post-operative year
|
1, 3, 6 and 12 month after lung transplantation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jens Gottlieb, Prof. Dr., Hannover Medical School
- Principal Investigator: Martina de Zwaan, Prof. Dr., Hannover Medical School
Publications and helpful links
General Publications
- EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208. doi: 10.1016/0168-8510(90)90421-9.
- Napolitano MA, Babyak MA, Palmer S, Tapson V, Davis RD, Blumenthal JA; Investigational Study of Psychological Intervention in Recipients of Lung Transplant (INSPIRE) Investigators. Effects of a telephone-based psychosocial intervention for patients awaiting lung transplantation. Chest. 2002 Oct;122(4):1176-84. doi: 10.1378/chest.122.4.1176.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.
- Lowe B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K, Schneider A, Brahler E. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010 Apr;122(1-2):86-95. doi: 10.1016/j.jad.2009.06.019. Epub 2009 Jul 17.
- Gazdag G, Horvath GG, Makara M, Ungvari GS, Gerlei Z. Predictive value of psychosocial assessment for the mortality of patients waiting for liver transplantation. Psychol Health Med. 2016 Jun;21(4):525-529. doi: 10.1080/13548506.2015.1109670. Epub 2015 Nov 7.
- Goetzmann L, Irani S, Moser KS, Schwegler K, Stamm M, Spindler A, Buddeberg C, Schmid C, Boehler A, Klaghofer R. Psychological processing of transplantation in lung recipients: a quantitative study of organ integration and the relationship to the donor. Br J Health Psychol. 2009 Nov;14(Pt 4):667-80. doi: 10.1348/135910708X399447. Epub 2009 Jan 24.
- Kugler C, Tegtbur U, Gottlieb J, Bara C, Malehsa D, Dierich M, Simon A, Haverich A. Health-related quality of life in long-term survivors after heart and lung transplantation: a prospective cohort study. Transplantation. 2010 Aug 27;90(4):451-7. doi: 10.1097/TP.0b013e3181e72863.
- Smith PJ, Blumenthal JA, Carney RM, Freedland KE, O'Hayer CVF, Trulock EP, Martinu T, Schwartz TA, Hoffman BM, Koch GG, Davis RD, Palmer SM. Neurobehavioral functioning and survival following lung transplantation. Chest. 2014 Mar 1;145(3):604-611. doi: 10.1378/chest.12-2127.
- Speckhart D, Solomon SR, Zhang X, Morris LE, Bashey A, Holland HK. The Psychosocial Transplant Evaluation Rating Scale (TERS) prospectively predicts inferior Overall survival outcome for high-risk scoring patients undergoing allogeneic hematopoietic stem cell Transplantation. Blood 2014; 124(21)
- Twillman RK, Manetto C, Wellisch DK, Wolcott DL. The Transplant Evaluation Rating Scale. A revision of the psychosocial levels system for evaluating organ transplant candidates. Psychosomatics. 1993 Mar-Apr;34(2):144-53.
- Yost GL, Bhat G, Ibrahim KN, Karountzos AG, Chandrasekaran M, Mahoney E. Psychosocial Evaluation in Patients Undergoing Left Ventricular Assist Device Implantation Using the Transplant Evaluation Rating Scale. Psychosomatics. 2016 Jan-Feb;57(1):41-6. doi: 10.1016/j.psym.2015.07.013. Epub 2015 Aug 1.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- DZL BREATH-EVALUT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Transplantation
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Emory UniversityCompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Heart-Lung TransplantationUnited States
-
Astellas Pharma IncCompletedHeart Transplantation | Lung Transplantation | Pancreas (Including SPK) TransplantationFrance, United Kingdom, Taiwan, Belgium, Italy, Austria
-
Hannover Medical SchoolUnknownExercise Training | Lung Transplantation | Psychotherapy | Heart-Lung Transplantation | "Rehabilitation"Germany
-
University of AlbertaNatera, Inc.; One LambdaRecruiting
-
Universidad Complutense de MadridHospital Universitario 12 de OctubreRecruiting
-
KU LeuvenCompleted
-
Hopital FochCompleted
-
Emory UniversityTerminated
-
Hannover Medical SchoolCorscience, Inc.CompletedLung TransplantationGermany